



JAGSONPAL PHARMACEUTICALS LIMITED

Regd. Office : T-210J, Shahpur Jat, New Delhi - 110 049 (INDIA)
Fax : 0091-11-26498341, 26494708, Phone : 0091-11-26494519-24
CIN No. L74899DLI978PLC009181

JPL/SEC/LODR-Comp/reS-Not1

Date : December 12th, 2017

The National Stock Exchange of India Ltd. Exchange Plaza, Bandara-Kurla Complex Bandra (E), Mumbai - 400 051. Ph. 022-26598452	The Bombay Stock Exchange Limited Pherozebhoj Jeejeebhoy Tower Dalal Street, Mumbai - 400 001 Ph. 022-22721234
SUB: UN-AUDITED STANDALONE FINANCIAL RESULTS FOR QUARTER ENDED 30.09.2017 & LIMITED REVIEW.	

Dear Sir,

Please find enclosed herewith un-audited financial results along with Limited Review for the quarter / half year ended 30th September, 2017.

Thanking you.

Yours faithfully,
for JAGSONPAL PHARMACEUTICALS LIMITED

R K KAPOOR
COMPLIANCE OFFICER CUM COMPANY SECRETARY

Encl. : As above.

Particulars	Standalone				
	Quarter Ended			Half Year Ended	
	30.09.2017	30.06.2017	30.09.2016	30.09.2017	30.09.2016
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited
1 Income from operations					
a Gross Sales/Revenue from Operations	2890.68	2696.78	4010.20	5587.46	8029.98
b Other Operating Income	0.00	0.00	14.02	0.00	27.17
Total Income from operations	2890.68	2696.78	4024.22	5587.46	8057.15
2 Other Income	17.21	12.15	0.06	29.36	0.09
3 Total Income [1+2]	2907.89	2708.93	4024.28	5616.82	8057.24
4 Expenses					
a Cost of materials consumed	1636.19	1803.09	1212.16	3439.28	2886.08
b Purchases of stock-in-trade	61.38	425.42	192.14	486.80	567.13
c Changes in inventories of finished goods, work in progress and Stock in trade	-146.34	-826.45	283.42	-972.79	-139.01
d Excise Duty	0.00	7.13	8.50	7.13	17.06
e Employee benefits expenses	1104.97	958.66	1011.44	2063.63	2127.55
f Finance Cost	19.15	18.63	87.07	37.78	161.94
g Depreciation and amortisation expense	1.89	26.47	72.80	28.36	143.23
h Other expenses	625.12	718.05	1094.02	1343.17	2130.18
Total expenses	3302.36	3131.00	3961.35	6433.36	7914.14
5 Profit before exceptional items and taxes (3-4)	-394.47	-422.07	62.93	-816.54	143.10
6 Exceptional items	0.00	0.00	0.00	0.00	0.00
7 Profit before tax [5-6]	-394.47	-422.07	62.93	-816.54	143.10
8 Tax expense	-9.13	0.00	12.60	-9.13	28.63
9 Net Profit for the period [7-8]	-385.34	-422.07	50.33	-807.41	114.47
10 Other Comprehensive Income					
A (i) Items that will not be classified to profit or loss	0.00	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will not be reclassified to profit and loss	0.00	0.00	0.00	0.00	0.00
11 Total Other Comprehensive income [A(i) + A(ii)]	0.00	0.00	0.00	0.00	0.00
12 Total Comprehensive income [9+11]	-385.34	-422.07	50.33	-807.41	114.47
13 Paid up Equity Share Capital (Face value Rs. 5/- per share)	1309.90	1309.90	1309.90	1309.90	1309.90
14 Earnings Per Share (before and after extraordinary items) (of Rs 5/- each)					
a. Basic (Rs.)	-1.47	-1.61	0.19	-3.08	0.44
b. Diluted (Rs.)	-1.47	-1.61	0.19	-3.08	0.44

(Rs in lakhs)

Statement of Assets and Liabilities	
Particulars	As on 30.09.2017
ASSETS	
1 Non-current assets	
(a) Property, Plant and Equipment	2104.51
(b) Capital Work-in-Progress	0.00
(c) Goodwill	3.00
(d) Intangible assets under development	288.02
(e) Financial assets	
(i) Investments	0.05
(f) Other non-current assets	1076.36
Total non-current assets	3471.94
2 Current assets	
(a) Inventories	5606.15
(b) Financial assets	
(i) Trade receivables	2649.20
(ii) Cash and Cash equivalents	612.78
(iii) Bank balances other than (ii) above	328.90
(c) Other current assets	298.28
Total current assets	9495.31
TOTAL ASSETS	12967.25

EQUITY AND LIABILITIES	
EQUITY	
(a) Equity Share Capital	1309.90
(b) Other Equity	
(i) Reserves & Surplus	8874.07
Total Equity	10183.97
LIABILITIES	
1 Non-current liabilities	
(a) Deferred tax liabilities (Net)	317.00



(b) Non current borrowings	0.00
Non-current liabilities	317.00
2 Current Liabilities	
(a) Financial Liabilities	
(i) Trade payables	1077.50
(ii) Other financial liabilities	874.07
(b) Provisions	514.71
Total current liabilities	2466.28
Total Liabilities	2783.28
TOTAL - EQUITY AND LIABILITIES	12967.25

Notes

- The above Financial Results were reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on December 12, 2017.
- In line with the provisions of Ind AS 108, the Company operates in one reportable business segment i.e. 'Pharmaceuticals'.
- Figures for the previous periods have been regrouped, wherever necessary, to correspond with the figures of the current period.
- The above results are available on website of the company www.jagsonpal.com and on the Website of BSE (www.bseindia.com) and NSE (www.nseindia.com).
- The Company has adopted Ind AS from April 1, 2017 and accordingly, these financial results have been prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 Interim Financial Reporting prescribed under section 133 of the Companies Act 2013, read with relevant rules issued thereunder. The date of transition to Ind AS is April 1, 2016. The impact of transition if any has been accounted for in the opening reserves and the comparative period results have been restated accordingly. The opening balance sheet as at April 1, 2016 and the results for the subsequent periods would be finalised and will be subject to audit at the time of annual financial statements for the year ended March 31, 2018.
- According to the requirements of Ind AS and SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, revenue for the corresponding previous quarter ended June 30, 2017 and September 30, 2016 for the six months ended September 30, 2016, were reported inclusive of Excise Duty. The Government of India has implemented Goods and Service Tax ("gst") from July 01, 2017 replacing Excise Duty, Service Tax and various indirect taxes. As per Ind AS 18, the revenue for the quarter ended September 30, 2017, is reported net of GST and is not comparable with previous reported quarter.
- Reconciliation between results previously reported under erstwhile Indian GAAP and as presented now under Ind AS are given below:-

Particulars	Quarter ended 30.09.2016	Year to date ended 30.09.2016
Net Profit for the period as per Indian GAAP		
Adjustments :	50.33	114.47
Net Profit for the period as per Ind AS	50.33	114.47
Total Comprehensive Income as per Ind AS	50.33	114.47

- The Ind AS compliant comparative figures for the quarter ended September 30, 2016 and Year to date September 30, 2016 have not been subjected to review or audit. However, the company's management has exercised necessary due diligence to ensure that such financial results provide true and fair view of its affairs.

Place : New Delhi
Date : 12-12-2017



By Order of the Board
For Jagsonpal Pharmaceuticals Limited

Rajpal Singh Kochhar
Managing Director
DIN No 00059492



To,

The Board of Directors
Jagsonpal Pharmaceuticals Limited
T-210-J, Shahpur Jat
New Delhi-110049.

1. We have reviewed the unaudited financial results of Jagsonpal Pharmaceuticals Limited (the "Company") for the quarter & half year ended September 30, 2017 which are included in the accompanying Statement of Standalone Financial Results for the quarter & half year ended September 30, 2017 and the statement of assets and liabilities on that date together with the notes thereon ((the "Statement"). The Statement has been prepared by the Company pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the Listing Regulations, 2015") and SEBI Circular dated July 5, 2016, which has been initialled by us for identification purposes. The Statement is the responsibility of the Company's management and has been approved by the Board of Directors. Further the Management is also responsible to ensure that the accounting policies used in preparation of this Statement are consistent with those used in the preparation of the Company's opening unaudited Balance Sheet as at April 1, 2016 prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS prescribed under section 133 of the Companies Act, 2013 and other recognized accounting practices and policies. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2014, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement.
3. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with Ind AS and other recognised accounting practices and policies, and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 and SEBI circular dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. We draw attention to the following matters :
 - a. The Statement which states that the Company has adopted Ind AS for the financial year commencing from April 1, 2017, and accordingly, the Statement has been prepared by the Company's Management in compliance with Ind AS.
 - b. We were neither engaged to review, nor have we reviewed the comparative figures including the reconciliation to the Total Comprehensive Income for the quarter ended on September 30, 2016 and accordingly, we do not express any conclusion on the results in the Statement for the quarter ended September 30, 2016. As set out in the Statement, these figures has been furnished by the Management.


Cont..2..



- c. The standalone financial statements of the Company for the year ended March 31, 2017 prepared in accordance with Companies (Accounting Standards) Rules, 2006, were audited by another firm of chartered accountants under the Companies Act, 2013 who, vide their report dated May 28, 2017, expressed an unmodified opinion on those financial statements.

Our conclusion is not qualified in respect of these matters.

For H.L. Bansal & Co.
Chartered Accountants,
FRN :08563N



Hira Lal Bansal
Proprietor
Membership No. 086990
Dated : 12.12.2017

